Literature DB >> 18160665

Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma.

Lloyd T Lam1, George Wright, R Eric Davis, Georg Lenz, Pedro Farinha, Lenny Dang, John W Chan, Andreas Rosenwald, Randy D Gascoyne, Louis M Staudt.   

Abstract

The activated B cell-like (ABC) subgroup of diffuse large B-cell lymphoma (DLBCL) is characterized by constitutive activation of the nuclear factor-kappaB (NF-kappaB) pathway. In this study, we showed that the NF-kappaB pathway induced the expression of the cytokines interleukin (IL)-6 and IL-10 in ABC DLBCL cell lines, which also have high levels of total and phosphorylated signal transducer and activator of transcription (STAT) 3 protein, suggesting autocrine signaling. Using RNA interference for STAT3, we defined a gene expression signature of IL-6 and IL-10 signaling through STAT3. Based on this signature, we constructed a molecular predictor of STAT3 signaling that defined a subset of ABC DLBCL tumors with high expression of STAT3, IL-6, and/or IL-10 and their downstream targets. Although the STAT3-high and STAT3-low subsets had equivalent expression of genes that distinguish ABC DLBCL from germinal center B cell-like DLBCL, STAT3-high ABC DLBCLs had higher expression of signatures that reflected NF-kappaB activity, proliferation, and glycolysis. A small-molecule inhibitor of Janus kinase signaling, which blocked STAT3 signature expression, was toxic only for ABC DLBCL lines and synergized with an inhibitor of NF-kappaB signaling. These findings suggest that the biological interplay between the STAT3 and NF-kappaB pathways may be exploited for the treatments of a subset of ABC DLBCLs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18160665      PMCID: PMC2275028          DOI: 10.1182/blood-2007-09-111948

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  60 in total

1.  Transcriptional regulation and function during the human cell cycle.

Authors:  R J Cho; M Huang; M J Campbell; H Dong; L Steinmetz; L Sapinoso; G Hampton; S J Elledge; R W Davis; D J Lockhart
Journal:  Nat Genet       Date:  2001-01       Impact factor: 38.330

Review 2.  Signatures of the immune response.

Authors:  A L Shaffer; A Rosenwald; E M Hurt; J M Giltnane; L T Lam; O K Pickeral; L M Staudt
Journal:  Immunity       Date:  2001-09       Impact factor: 31.745

3.  Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma.

Authors:  J Iqbal; T C Greiner; K Patel; B J Dave; L Smith; J Ji; G Wright; W G Sanger; D L Pickering; S Jain; D E Horsman; Y Shen; K Fu; D D Weisenburger; C P Hans; E Campo; R D Gascoyne; A Rosenwald; E S Jaffe; J Delabie; L Rimsza; G Ott; H K Müller-Hermelink; J M Connors; J M Vose; T McKeithan; L M Staudt; W C Chan
Journal:  Leukemia       Date:  2007-07-12       Impact factor: 11.528

Review 4.  Interleukin-10 and the interleukin-10 receptor.

Authors:  K W Moore; R de Waal Malefyt; R L Coffman; A O'Garra
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

5.  Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.

Authors:  Brian F Skinnider; Andrew J Elia; Randy D Gascoyne; Bruce Patterson; Lorenz Trumper; Ursula Kapp; Tak W Mak
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

6.  BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control.

Authors:  A L Shaffer; X Yu; Y He; J Boldrick; E P Chan; L M Staudt
Journal:  Immunity       Date:  2000-08       Impact factor: 31.745

Review 7.  The role of STATs in transcriptional control and their impact on cellular function.

Authors:  J Bromberg; J E Darnell
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

8.  Tissue-specific autoregulation of the stat3 gene and its role in interleukin-6-induced survival signals in T cells.

Authors:  M Narimatsu; H Maeda; S Itoh; T Atsumi; T Ohtani; K Nishida; M Itoh; D Kamimura; S J Park; K Mizuno; J Miyazaki; M Hibi; K Ishihara; K Nakajima; T Hirano
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

9.  Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.

Authors:  R E Davis; K D Brown; U Siebenlist; L M Staudt
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

10.  Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol.

Authors:  L T Lam; O K Pickeral; A C Peng; A Rosenwald; E M Hurt; J M Giltnane; L M Averett; H Zhao; R E Davis; M Sathyamoorthy; L M Wahl; E D Harris; J A Mikovits; A P Monks; M G Hollingshead; E A Sausville; L M Staudt
Journal:  Genome Biol       Date:  2001-09-13       Impact factor: 13.583

View more
  162 in total

Review 1.  Oncogenic activation of NF-kappaB.

Authors:  Louis M Staudt
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-21       Impact factor: 10.005

Review 2.  Pathogenesis of diffuse large B cell lymphoma.

Authors:  Wing John C Chan
Journal:  Int J Hematol       Date:  2010-06-29       Impact factor: 2.490

3.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

Review 4.  HiJAKing the epigenome in leukemia and lymphoma.

Authors:  Amanda C Drennan; Lixin Rui
Journal:  Leuk Lymphoma       Date:  2017-04-12

5.  Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.

Authors:  Chi Young Ok; Ling Li; Zijun Y Xu-Monette; Carlo Visco; Alexander Tzankov; Ganiraju C Manyam; Santiago Montes-Moreno; Karen Dybkaer; Karen Dybaer; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Jiayu Chen; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Jooryung Huh; Weiyun Ai; Maurilio Ponzoni; Andrés J M Ferreri; John P Farnen; Michael B Møller; Carlo E Bueso-Ramos; Roberto N Miranda; Jane N Winter; Miguel A Piris; L Jeffrey Medeiros; Ken H Young
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

Review 6.  Diffuse large B-cell lymphoma-treatment approaches in the molecular era.

Authors:  Mark Roschewski; Louis M Staudt; Wyndham H Wilson
Journal:  Nat Rev Clin Oncol       Date:  2013-11-12       Impact factor: 66.675

7.  Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease regions.

Authors:  Therese Högfeldt; Crystal Jaing; Kevin Mc Loughlin; James Thissen; Shea Gardner; Abeer A Bahnassy; Baback Gharizadeh; Joachim Lundahl; Anders Österborg; Anna Porwit; Abdel-Rahman N Zekri; Hussein M Khaled; Håkan Mellstedt; Ali Moshfegh
Journal:  Oncol Lett       Date:  2016-08-16       Impact factor: 2.967

8.  The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.

Authors:  Michael Hedvat; Dennis Huszar; Andreas Herrmann; Joseph M Gozgit; Anne Schroeder; Adam Sheehy; Ralf Buettner; David Proia; Claudia M Kowolik; Hong Xin; Brian Armstrong; Geraldine Bebernitz; Shaobu Weng; Lin Wang; Minwei Ye; Kristen McEachern; Huawei Chen; Deborah Morosini; Kirsten Bell; Marat Alimzhanov; Stephanos Ioannidis; Patricia McCoon; Zhu A Cao; Hua Yu; Richard Jove; Michael Zinda
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

9.  High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.

Authors:  Lesley A Mathews Griner; Rajarshi Guha; Paul Shinn; Ryan M Young; Jonathan M Keller; Dongbo Liu; Ian S Goldlust; Adam Yasgar; Crystal McKnight; Matthew B Boxer; Damien Y Duveau; Jian-Kang Jiang; Sam Michael; Tim Mierzwa; Wenwei Huang; Martin J Walsh; Bryan T Mott; Paresma Patel; William Leister; David J Maloney; Christopher A Leclair; Ganesha Rai; Ajit Jadhav; Brian D Peyser; Christopher P Austin; Scott E Martin; Anton Simeonov; Marc Ferrer; Louis M Staudt; Craig J Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

Review 10.  New insights into the regulation of human B-cell differentiation.

Authors:  Heike Schmidlin; Sean A Diehl; Bianca Blom
Journal:  Trends Immunol       Date:  2009-05-15       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.